We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Durect has begun dosing in a Phase II trial of Transdur-Bupivacaine (DUR-843), a transdermal pain patch for patients suffering from post-herpetic neuralgia (PHN).
Allos Therapeutics announced that an independent data monitoring committee (DMC) has completed a planned interim analysis of safety data from the company's pivotal Phase II PROPEL trial of PDX (pralatrexate) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and has recommended that the trial continue per the protocol.
Neurocrine Biosciences announced positive preliminary results from its second proof-of-concept, safety and efficacy Phase II clinical trial over a three-month treatment period using its proprietary, orally active nonpeptide Gonadotropin-Releasing Hormone receptor antagonist (NBI-56418) in patients with endometriosis.
Mylan Laboratories announced that the FDA has granted the company approval to market levothyroxine sodium tablets, which are therapeutically equivalent to Forest Laboratories' Levothroid Tablets.
Innovive Pharmaceuticals has announced that the FDA has granted orphan drug designation to the company's Phase I drug candidate INNO-406, an orally bioavailable dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec-resistant or intolerant chronic myelogenous leukemia.
ImClone Systems has initiated patient treatment in a Phase I clinical trial of its fully human IgG1 monoclonal antibody targeting the platelet derived growth factor receptor (PDGFR) alpha, IMC-3G3, in patients with solid tumors.
Genaera has announced that, following a comprehensive review of its development portfolio and external market conditions, its board of directors and management have determined that it is in the best interest of the company to terminate the Evizon (squalamine lactate) clinical development program in wet age-related macular degeneration (AMD).